Related Experiment Video

Updated: Sep 10, 2025

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice
11:57

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Published on: July 23, 2017

10.2K

DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled

Stine Holmen1, Olivier Manintveld2, Kevin Damman3

  • 1Department of Cardiology, Oslo University Hospital, Oslo, Norway; Department of Medicine, Innlandet Hospital Trust, Hamar, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.

American Heart Journal
|August 21, 2025
PubMed

Insights

The DAPARHT trial investigates if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can protect kidney function in heart transplant recipients. This study will provide the first randomized evidence on SGLT2i efficacy in this population.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Heart transplantation is a vital treatment for end-stage heart failure.
  • Kidney function frequently declines post-heart transplantation.
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are known to slow kidney function decline in other patient groups.

Purpose of the Study:

  • To evaluate the effect of dapagliflozin on kidney function in heart transplant recipients.
  • To assess the efficacy of SGLT2i in preserving estimated glomerular filtration rate (eGFR) after heart transplantation.

Main Methods:

  • The DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT) trial is a double-blind, randomized, placebo-controlled study.
  • Adult heart transplant recipients (at least one year post-transplant, eGFR ≥ 25 mL/min/1.73m² ) will receive 10 mg dapagliflozin or placebo for 12 months.
  • The primary endpoint is the chronic slope of eGFR from two weeks to 12 months; a 24-month open-label phase will follow.

Main Results:

  • Enrollment is ongoing, with 300 of 430 patients enrolled as of December 18th, 2024.
  • Mean baseline creatinine is 104 ± 28 μmol/L, with a mean eGFR of 66 ± 22 mL/min/1.73m².
  • The study is expected to conclude with the last patient visit in September 2028.

Conclusions:

  • The DAPARHT trial will provide the first randomized evidence on the efficacy of SGLT2i in heart transplant recipients.
  • The study aims to determine if dapagliflozin can improve the eGFR slope compared to placebo over one year.
Abstract

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

27.9K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
60
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
819
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23